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Aims The effect of combined cytokine and cell therapy in ischaemic cardiomyopathy is unknown. Meta-analyses suggest
improved cardiac function with cell therapy. The optimal cell delivery route remains unclear. We investigated whether
granulocyte colony-stimulating factor (G-CSF) alone or in combination with intracoronary (i.c.) or intramyocardial
(i.m.) injection of autologous bone marrow-derived cells (BMCs) improves cardiac function.
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Methods
and results
Ninety patients with symptomatic ischaemic cardiomyopathy and no further treatment options were enrolled in
the randomized, placebo-controlled, single-centre REGENERATE-IHD study. Randomization was to one of three
arms: peripheral, i.c., or i.m. In each arm, patients were randomized to active treatment or placebo. All patients,
apart from the peripheral placebo group (saline only) received G-CSF for 5 days. The i.c. and i.m. arms received
either BMCs or serum (placebo). The primary endpoint was change in LVEF at 1 year assessed by cardiac magnetic
resonance imaging/computed tomography. The i.m. BMC group showed a significant improvement in LVEF of 4.99%
(95% confidence interval 0.33–9.6%; P = 0.038) at 1 year. This group also showed a reduction in NYHA class at
1 year and NT-proBNP at 6 months. No other group showed a significant change in LVEF. This finding is supported
by post-hoc between-group comparisons.
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Conclusion We have shown that G-CSF combined with autologous i.m. BMCs has a beneficial effect on cardiac function and
symptoms. However, this result should be considered preliminary in support of a clinical benefit of i.m. stem cell
infusion in ‘no option’ patients and needs further exploration in a larger study.
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Introduction
One of the principal causes of heart failure in developed countries
is ischaemic heart disease.1 Despite advances in treatment, the
prognosis for patients who are admitted to hospital with heart
failure remains poor, with a 5-year survival of ∼50% and a 10-year
survival of ∼10%.2,3 The increasing prevalence of heart failure
poses a significant burden to patients, practitioners, and healthcare
systems, and hence defines a need for new or improved treatments
in patients with no further treatment options.
A number of small trials have evaluated the role of the cytokine
granulocyte colony-stimulating factor (G-CSF) alone in improve-
ment of cardiac function in ischaemic heart failure; however, the
overall results have been mixed.4–8 Following early trials showing
beneficial effects of cell therapy in acute myocardial infarction
(MI),9,10 Phase I/II trials using infusion of autologous progen-
itor cells in ischaemic cardiomyopathy have shown promising
results.11–13 However, these studies have often lacked an appro-
priate comparison group for the interventions used. Meta-analysis
confirms an improvement in cardiac function of patients with
autologous cells and also that the intramyocardial route of delivery
is most effective.14–17 Only a small number of trials have assessed
the use of cytokine therapy as an adjunct to cell therapy, of which
none is fully controlled.15,17
In the exploratory randomized, placebo-controlled
REGENERATE-IHD trial, we sought to address for the first
time whether G-CSF alone or combined with cell therapy has
a beneficial effect on cardiac function in patients with ischaemic
cardiomyopathy who have no further treatment options but
remain symptomatic. The trial design was modelled on the
recently published REGENERATE-DCM trial,18 a study assessing
the combination of cytokine and cell therapy in patients with
non-ischaemic cardiomyopathy.
Methods
Study design and patient selection
The REGENERATE-IHD trial is an investigator-initiated, single-centre,
randomized, placebo-controlled trial. The trial assessed whether
G-CSF administration alone or in combination with either the intra-
coronary (i.c.) or targeted intramyocardial (i.m.) injection of autolo-
gous bone marrow-derived cells (BMCs) leads to an additional benefit
on cardiac function compared with placebo controls. Following a pilot
study to address safety and feasibility,19 the trial was approved by an
independent ethics committee (REC no. 04/Q0603/13), the Medicines
and Healthcare Products Regulatory Agency (MHRA), registered
at approved registries (ClinicalTrials.gov: NCT00747708; EudraCT:
2005-002706-27), and was performed in accordance with the Declara-
tion of Helsinki (1993) and the principles of the International Confer-
ence of Harmonization–Good Clinical Practice (ICH-GCP) guidelines.
Details of the trial protocol have been published previously.20
Patients were referred to the trial with a confirmed diagnosis of
heart failure from local heart failure clinics. Inclusion criteria were
a confirmed diagnosis of ischaemic heart failure (including diffuse
coronary stenoses and extensive infarcted myocardium), on optimal
medical treatment (for at least 6 months), documented impaired
LVEF, NYHA class II–IV, with no further treatment/revascularization ..
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.. options (for a complete list, see the Supplementary material online,
Methods).
Randomization, masking, and treatment
After consenting for the trial, patients underwent a two-stage ran-
domization process using a dedicated trial software system (IHD,
Bishops Stortford, Herts, UK). First, they were randomized to one
of three treatment arms: the peripheral arm, the i.c arm, or the i.m.
arm independent of coronary anatomy. Once allocated to a treatment
arm, patients were further randomized (1:1) to either the active
treatment or the placebo group. If after first randomization, patients
were found to be unsuitable for their assigned treatment arm on the
basis of further trial investigations, they would be withdrawn at this
stage. Accordingly, patients randomized to the peripheral arm were
further randomized to receive 5 days of either subcutaneous injected
saline or subcutaneous G-CSF (Granocyte™, Chugai Pharmaceutical
Ltd, Mulliner House, London, UK) (10 μg/kg/day). Patients who were
randomized to either the i.c. or i.m. treatment arms all received
5 days of subcutaneous G-CSF followed by bone marrow harvest
within 24 h of completing treatment. A 50mL aliquot of bone marrow
was aspirated from the iliac crest under local anaesthetic, and an
additional 30mL of blood was taken to provide serum for the placebo
group. The aspirate and blood were sent to the designated stem cell
laboratory where patients were further randomized to receive either
autologous BMCs or serum (1:1 within each arm). Bone marrow
mononuclear cells were isolated by density gradient centrifugation,
washed, and resuspended in autologous serum at a final volume of
10mL (i.c.) or 2mL (i.m.). The cell product/serum was injected via
either i.c. or i.m. routes within 24 h of bone marrow harvest. The
i.c. delivery was in equal amounts into three patent coronary vessels
during stop flow conditions.9 The i.m. cell product/serum was injected
via the MyoStar™ catheter (Biologics Delivery Systems Group, Cordis
Corporation, Diamond Bar, CA, USA) into border zones around scar
tissue, guided by electromechanical mapping using the NOGA® XP
Cardiac Navigation System. The total 2mL volume was delivered
equally to 10 target areas at ∼1 cm intervals. (For further information
see Figure 1 and the Supplementary material online, Methods).
Patients within each arm remained blinded to the therapy they
received. Both the i.c. and i.m. arms were double blinded, with patients,
investigators, and treating clinicians blinded to group assignment
(cells/serum). Due to daily full blood count monitoring during G-CSF
treatment, the peripheral arm remained single blinded only. Data anal-
ysers were entirely masked to group assignment in all trial arms.
Endpoints and definitions
The primary endpoint for all patients was the change in LVEF at 12
months compared with baseline (prior to commencing G-CSF, or
placebo in the peripheral placebo group) as measured using cardiac
magnetic resonance imaging (CMR) or computed tomography (CT; for
those unable to undergo CMR). Secondary endpoints included change
in NYHA class, quality of life (QoL) (EQ5D®, SF-36®, and MacNew®
questionnaires), and LVEF by contrast transthoracic echocardiography
at 6 months and 1 year compared with baseline, as well as NT-proBNP
and, in the i.c. and i.m. arms only, quantitative left ventriculography at
6 months compared with baseline. Safety endpoints included major
adverse cardiac events (MACE: cardiac death, MI, PCI, or coronary
artery bypass grafting) or any significant arrhythmias (symptomatic ven-
tricular tachycardia or survived cardiac death) at 6 months and 1 year.
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 CONSORT diagram. Flow chart of the study summarizing flow of patients through the trial. BMC, bone marrow-derived cells; C,
cardiac; G-CSF, granulocyte colony-stimulating factor; HF, heart failure; IC, intracoronary; IM, intramyocardial; NC, non-cardiac.
Advanced cardiac imaging
Cardiac magnetic resonance imaging, or cardiac CT for those unable
to undergo CMR (e.g. cardiac devices, claustrophobia, etc.) were
performed at baseline and 12 months. Multiphase cardiac data sets
with full LV coverage were acquired using standard protocols21,22 (see
the Supplementary material online, Methods). Images were analysed in
blinded fashion by two experienced operators. The standard error of
measurement of CMR and CT was 1.93% and 2.3%, respectively.
Statistical design and analyses
The study was powered to detect a 3.5% within-group improvement
in the primary endpoint, i.e. change in LVEF at 12 months based on
changes seen in a contemporary trial of cell therapy.23 Based on a
power of 90%, a significance level of 5% and an estimated variance
of 4% (assuming pre- and post-treatment means are uncorrelated), the
calculated required number of patients in each group was 11. It was .
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. estimated that an additional four per group would be needed in order
to ensure that 11 patients reached the primary endpoint at 1 year,
resulting in a size of 15 patients per treatment group.
A paired t-test was used to detect any statistical significance of
within-group changes in LVEF. For additional analyses using contin-
uous variables, appropriate parametric (paired t-test for paired, and
independent samples t-test for unpaired data) and non-parametric
(Wilcoxon sign-rank test for paired, Mann–Whitney for unpaired
data, and Kruskal–Wallis test for more than two groups) tests were
used. 𝜒2 or Fisher’s exact tests were used for categorical variables.
For post-hoc between-group comparisons, one-way analysis of vari-
ance (ANOVA) was used with Dunnett’s adjustment for multiple
comparisons with a significance level of 0.2 where all treatment groups
were compared with the peripheral placebo group as a ‘control’.
Where post-hoc analysis was performed without a ‘control’ group
comparison, a one-way ANOVA was used with Holm–Sidak
adjustment for multiple comparisons with a significance level of 0.2.
Pearson’s linear regression was used for comparison between LVEF
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Baseline characteristics
Saline
(n=15)
G-CSF
(n=15)
i.c. serum
(n=15)
i.c. BMC
(n=15)
i.m. serum
(n=15)
i.m. BMC
(n=15)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age, years (mean± SD) 63.3± 9.3 63.1± 8.2 62.8±10.7 62.1± 9.7 60.4±11.2 65.3± 9.4 0.841
Sex M/F, n 14/1 13/2 14/1 14/1 15/0 15/0 0.896
BMI (kg/m2) (mean± SD) 29.5± 4.3 31.4± 6.0 31.7± 6.5 29.7± 4.8 29.6± 3.7 30.8± 4.0 0.739
Medical history, n (%)
Hypertension 3 (20.0) 1 (6.7) 2 (13.3) 3 (20.0) 5 (33.3) 5 (33.3) 0.414
Diabetes 4 (26.7) 5 (33.3) 2 (13.3) 2 (13.3) 4 (26.7) 4 (26.7) 0.748
CABG 5 (33.3) 4 (26.7) 3 (20.0) 7 (46.7) 6 (40.0) 4 (26.7) 0.653
MI 13 (86.7) 12 (80.0) 14 (93.3) 13 (86.7) 13 (86.7) 13 (86.7) 0.949
Hypercholesterolaemia 4 (26.7) 6 (40.0) 5 (33.3) 5 (33.3) 8 (53.3) 4 (33.3) 0.715
Smoker/ex-smoker 12 (80.0) 8 (53.3) 13 (86.7) 11 (73.3) 14 (93.3) 11 (73.3) 0.150
Time from last MI, days median (IQR) 1307 (1064–5443) 2527 (966–4928) 2856 (1278–6041) 1805 (896–3855) 2406 (706–5402) 2684 (706–5402) 0.964
LVEF (%) (mean± SD) 34.7±10.1 27.9±12.4 31.6± 7.4 31.7± 8.8 29.0± 9.2 28.6±10.2 0.385
Number of devices, n (%)
CRT-D 4 (26.7) 5 (33.3) 4 (26.7) 4 (26.7) 3 (20.0) 7 (46.7) 0.781
CRT-P 1 (6.7) 1 (6.7) 0 (0) 0 (0) 0 (0) 0 (0) 0.999
ICD only 7 (46.7) 2 (13.3) 4 (26.7) 5 (33.3) 5 (33.3) 6 (40.0) 0.485
Medication history, n (%)
Statin 12 (80.0) 13 (86.7) 13 (86.7) 13 (86.7) 14 (93.3) 13 (86.7) 0.995
ACE inhibitor/ARB 14 (93.3) 14 (93.3) 13 (86.7) 14 (93.3) 15 (100) 15 (100) 0.896
Beta-blocker 15 (100.0) 14 (93.3) 12 (80.0) 15 (100.0) 11 (73.3) 14 (93.3) 0.079
Aldosterone antagonist 9 (60.0) 13 (86.7) 9 (60.0) 12 (80.0) 9 (60.0) 12 (80.0) 0.351
Diuretics 10 (66.7) 11 (73.3) 13 (86.7) 12 (80.0) 8 (53.3) 12 (80.0) 0.363
NYHA at baseline, n (%) 0.393
II 10 (66.7) 9 (60.0) 5 (33.3) 8 (53.3) 11 (73.3) 8 (53.3)
III 4 (26.7) 6 (40.0) 10 (66.7) 7 (46.7) 4 (26.7) 6 (40.0)
IV 1 (6.7) 0 (0) 0 (0) 0 (0) 0 (0) 1 (6.7)
NT-proBNP (pg/mL) median (IQR) 600 (245–1691) 930 (457–1782) 812 (364–1632) 423 (241–577) 567 (237–1015) 634 (313–2038) 0.199
BMI, body mass index; CABG, coronary artery bypass graft; F, female; G-CSF, granulocyte colony-stimulating factor; i.c., intracoronary; ICD, implantable cardioverter defibrillator; i.m., intramyocardial;
IQR, interquartile range; M, male; MI, myocardial infarction.
and cell function variables. Values are quoted as mean± SD unless oth-
erwise stated. All P-values are two sided, and P< 0.05 is considered to
indicate statistical significance except for post-hoc between-group anal-
ysis. Statistical analyses were performed using SPSS® version 21 (IBM
Corp., Armonk, NY, USA) and graphs were produced using Graphpad
Prism® version 5.0 (GraphPad Software, San Diego, CA, USA).
Results
Patient population
A total of 1133 patients were referred from heart failure clinics
throughout the UK. Ot these, 1028 were ineligible: non-ischaemic
aetiology (n= 79), NYHA class< II/normal LVEF (n= 236), AF
(n= 27), refusal to participate in the trial (n= 389), death before
formal consent (n= 53), and other co-morbidities (n= 244). Of the
105 patients who were randomized, 15 patients were withdrawn
because of either unsuitability for the intervention or patient with-
drawal. Ninety received the allocated trial intervention (Figure 1).
The mean age of the patient population was 62.8± 9.6 years,
while the majority of patients were male (94.4%). The baseline
characteristics were similar across the groups, with a mean LVEF
of 30.6% [95% confidence interval (CI) 28.53–32.74], a mean
NT-proBNP of 1187.0± 179.9 pg/mL, and 97.8% of patients in
NYHA class II/III. Baseline patient demographics are shown in
Table 1. The majority of patients were on optimal medical therapy
(as per ESC guidelines),24 and there were no significant differences .
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. across groups in prescribed medication, implanted device therapy,
or rates of LV assessment by CMR or cardiac CT. At 1 year, a total
of 82 patients were assessed for the primary endpoint (Figure 1).
Left ventricular ejection fraction
Twenty-six patients underwent CMR assessment of cardiac func-
tion and the remainder CT assessment. Only patients treated in
the i.m. BMC group met the primary endpoint of change in LVEF
(increase of 4.99%; 95% CI 0.33–9.6%; P= 0.038, Figure 2; Supple-
mentary material online, Table S1). A trend to improvement in LVEF
was seen in the i.m. serum group (4.15%; 95% CI −3.3–11.6%;
P= 0.246). Importantly no change was seen in the i.c. BMC-treated
group (0.89%; 95% CI −2.2 to −3.9%; P= 0.541) or the periph-
eral groups: G-CSF (−1.25; 95% CI −5.4 to −2.9%; P= 0.520) and
placebo (−0.98%; 95% CI −4.4 to −2.5%; P= 0.551).
There were no significant changes in LV end-diastolic or
end-systolic volumes (LVEDV and LVESV) over time in any
treatment group (Supplementary material online, Table S1). The
improvements in cardiac function in the i.m. BMC group were also
seen using echocardiography, with no improvement seen in any
other treatment group (Supplementary material online, Figure S1).
In post-hoc between-group analysis, there was an absolute
improvement in LVEF of 5.97% in the i.m. BMC group compared
with the peripheral placebo group (P= 0.1867), not seen in the
other groups (Table 2). In post-hoc analysis comparing patients
treated with cells (i.c./i.m.), G-CSF (alone or in combination with
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Primary endpoint analysis of LVEF. LVEF at baseline and 1 year as measured using cardiac magnetic resonance imaging/computed
tomography in each of the treatment groups. BMC, bone marrow-derived cells; G-CSF, granulocyte colony-stimulating factor; IC, intracoronary;
IM, intramyocardial. *P< 0.05. Large filled circles represent the means at baseline and 1 year for each group, respectively, error bars represent
95% confidence intervals.
i.c./i.m. serum), and peripheral placebo, there were no differences
in improvement in LVEF. However, post-hoc comparisons between
the three trial arms (peripheral, i.c., and i.m.) revealed that patients
treated with combination G-CSF and i.m. injection (cells/serum)
showed significant improvement in LVEF compared with the
peripheral trial arm (absolute difference: 5.77%, P= 0.0165) and
the i.c. trial arm (absolute difference: 3.60%, P= 0.1477) with an
overall significant ANOVA of P= 0.0193 (Supplementary material
online, Table S1).
Plasma N-terminal pro brain natriuretic
peptide concentration
Statistical analysis was performed after logarithmic transforma-
tion of NT-proBNP values due to a non-normal distribution .
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. (untransformed baseline values in Table 1). At 6 months, only
patients in the i.m. BMC group showed a significant decrease
in NT-proBNP (977.5± 866.8 to 768.4± 754.4; P= 0.018). The
remaining groups showed no change (Figure 3). There were no
between-group differences seen in post-hoc analysis (Supplemen-
tary material online, Table S5).
New York Heart Association
and Canadian Cardiovascular Society
class
In the i.m. BMC group, there was a significant improvement in
NYHA class at 6 months (−0.57; P= 0.025), maintained at 1 year
(−0.50; P= 0.048). A significantly better improvement in NYHA
class was also seen in the i.m. BMC group compared with peripheral
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Post-hoc analysis of the between-group
changes in left ventricular ejection fraction
Treatment groups
compared with
peripheral placebo
Within-
group
change
Absolute
change
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Peripheral placebo −0.98 – –
Peripheral G-CSF −1.25 −0.43 0.9998
i.c. serum 1.10 +2.08 0.9272
i.c. BMC 0.89 +1.88 0.9439
i.m. serum 4.15 +5.14 0.2791
i.m. BMC 4.99 +5.97 0.1500*
Overall ANOVA (15
comparisons)
0.1645
Significance assessed by one-way analysis of variance (ANOVA) and Dunnett’s
adjustment for multiple comparisons with a significance level of <0.2.
G-CSF, granulocyte colony-stimulating factor; i.c., intracoronary; i.m., intramy-
ocardial.
*represents significance p< 0.2 (Dunnett’s adjustment for multiple comparisons).
placebo in post-hoc analysis (P=1284; Supplementary material
online, Table). In the i.m. serum group, a significant reduction in
NYHA class was seen at 6 months (−0.47; P= 0.016) but this was
not sustained at 1 year (−0.15; P= 0.451). In all other groups,
no change in NYHA class was seen (Figure 4; Supplementary
material online, Table S2). There was no change in Canadian
Cardiovascular Society (CCS) class at 6 months or 1 year in any
group (Supplementary material online, Figure S2; Table S5).
Quality of life questionnaires
The i.m. BMC group showed an improvement in QoL as assessed by
the physical well-being score in the SF-36® questionnaire at 1 year.
At 1 year, the i.c. BMC group showed a significant improvement in
the MacNew® and the i.c. placebo group showed an improvement
in the SF-36® physical well-being score. Neither the i.m. placebo
group nor the peripheral groups showed improvement in QoL at 1
year (Supplementary material online, Table S3). In post-hoc analysis,
the only significant between-group difference in QoL when com-
pared with peripheral placebo was seen as an improvement at 6
months in the i.m. BMC group using the SF-36® physical well-being
questionnaire (P= 0.0421; Supplementary material online, Table
S5). No other treatment groups showed a better response than
peripheral placebo.
Cell data
There was a trend towards a higher peripheral mononuclear cell
count after 5 days of G-CSF in the i.m. peripheral group (P= 0.049).
No other differences were observed in G-CSF-treated patients.
A breakdown of flow cytometric cellular analysis is given in the
Supplementary material online, Table S6. The mean total number
of cells injected in the two stem cell groups was 115.1× 106
mononuclear cells. The mean viability of processed cells was 98.2%.
There were no significant differences in cell numbers injected ..
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.. in the i.c. or i.m. group. No correlation was found between
the cell type injected and change in LVEF in any of the groups.
A significant correlation was observed between the number of
colony-forming unit granulocyte–monocyte (CFU GM) colonies
and the improvement in LVEF in the i.m. BMC group (Pearson
r= 0.79; P= 0.02) (Figure 5). No correlation was observed between
bone marrow CFU GM and change in LVEF in the i.c. BMC group.
Safety
A small increase in post-procedural troponin was detected in
the i.m. arms (0.02± 0.04; P= 0.007). However, there was no
significant difference in troponin increase between the two groups
and it was not associated with a rise in creatine kinase (from
85.1 to 129.5; P= 0.102). No clinical events occurred during the
procedures. No increases in cardiac enzymes were seen in any
other treatment arm. No significant differences in procedural
complication rates (P= 0.413), significant arrhythmias (P= 0.896),
or rates of MACE (P= 0.539) were noted between the groups.
MACE rates were low for all groups (one cardiovascular death in
the G-CSF group and one MI in the i.c. placebo group).
Discussion
The REGENERATE-IHD randomized trial is an early stage
exploratory placebo-controlled trial assessing the beneficial
effects of a combination of cytokine and cell therapy directly
comparing two different delivery routes in patients with advanced
heart failure, a group with no further treatment options. Due to
the sample size, the results should be seen as exploratory findings
that will need confirmation in larger focused trials. Nevertheless,
patients treated with G-CSF therapy and i.m. cell delivery for
5 days demonstrated a 4.99% within-group increase in LVEF at
1 year. This improvement in LV function was accompanied by a
sustained reduction in NYHA class at 1 year, associated with sig-
nificant improvement in QoL scoring and the biochemical marker
NT-proBNP, making a clinical benefit in this treatment group more
likely. Recognizing the limitations of within-group analyses with
small sample size,25 exploratory post-hoc between-group analy-
ses were also performed. In support of the primary outcomes,
post-hoc analysis demonstrated a 5.97% absolute improvement in
LVEF in the i.m. BMC group compared with the peripheral placebo
group, a group which could be considered the true control. No
other treatment group showed evidence of either within-group
improvement in LVEF at 1 year or between-group improvement in
LVEF when compared with the peripheral placebo group. Impor-
tantly, although the change in LVEF would appear to be relatively
low, the magnitude of effect is similar to that seen in other trials
of heart failure therapies (e.g. ACE inhibitors), which are now part
of standard practice.26
Together with inducing stem cell mobilization, G-CSF has also
been postulated as an independent therapeutic agent in ischaemic
cardiomyopathy, with previous studies suggesting an associated
improvement in LVEF.7 These studies have either lacked appropri-
ate controls or have not been randomized.4–8,27 In the exploratory
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Figure 3 NT-proBNP. Box and whisker plots showing NT-proBNP (pg/mL) at baseline and 6 months (median and range on a logarithmic
scale). BMC, bone marrow-derived cells; G-CSF, granulocyte colony-stimulating factor; IC, intracoronary; IM, intramyocardial. *P< 0.05.
REGENERATE-IHD trial findings reported here, G-CSF treatment
has no beneficial effect on functional, clinical and biochemical
markers of heart failure in this patient population either within
group or compared with peripheral placebo. However, it could
be suggested that G-CSF has an incremental effect due to the
additional benefit of a several fold increase in circulating mononu-
clear cell and CD34+ cell counts or the increase in cell counts
including CD34+ cell counts in the final injected cell product
as a result of G-CSF mobilization.28 This is supported by the
improvement seen in LVEF at 1 year in the i.m. placebo group of
4.1% which although non-significant may be attributed to higher
G-CSF-induced peripheral mononuclear cell counts achieved in
this treatment group compared with all other groups (0.049).
The findings of REGENERATE-IHD are in keeping with recent
meta-analysis data in ischaemic heart failure, showing a 5.30%
improvement in LVEF associated with i.m. cell injection compared
with 3.19% improvement using the i.c. route.14–17 Intramyocardial
injection has been shown to be associated with higher cell reten-
tion rates within the myocardium than other delivery routes (11% .
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.. compared with 3% with i.c. delivery).29 In chronic ischaemic car-
diomyopathy, i.m. injection may be more effective by providing a
targeted approach, thereby overcoming the lack of chemoattrac-
tive homing signals (that are more pronounced in acute ischaemia)
as well as bypassing the requirement to adhere to and pene-
trate the endothelium. Furthermore, in this setting, the target
myocardium may not be subtended by a patent coronary or col-
lateral vessel, precluding the utility of i.c. delivery. It is interesting
that the i.m. serum group shows a 4.15% improvement in LVEF
at 1 year and an absolute change in LVEF of 5.14% over periph-
eral placebo, neither of which reach significance. However, when
grouped by trial treatment arm (i.m. serum/cells) compared with
the i.c. arm and peripheral arm, patients who received i.m. injec-
tion of either cells or serum demonstrate significantly improved
LVEF. While this post-hoc analysis is exploratory and underpow-
ered, it does support the superiority of the i.m. approach over i.c.
delivery and seems to suggest a benefit of i.m. injection that is cell
independent. It could therefore be hypothesized that the targeted
i.m. injection of autologous serum after 5 days of treatment with
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 4 NYHA class. Mean NYHA class at baseline, 6 months, and 1 year shown for each of the treatment groups. BMC, bone
marrow-derived cells; G-CSF, granulocyte colony-stimulating factor; IC, intracoronary; IM, intramyocardial. *P< 0.05.
G-CSF may contain reparative cytokines and growth factors that
play a role in recovery of cardiac function. However, the correla-
tion between cell function (CFU assay) and change in LVEF in the
i.m. BMC group also provides evidence for cellular involvement in
sustained improvement in cardiac function. The observed improve-
ment in LVEF would suggest favourable reverse LV remodelling,
although the magnitude of the improvement and the small study
size may explain the fact that changes in LVESV and LVEDV were
not detected.
The baseline characteristics and disease parameters including
LVEF (<30%) were consistent with an advanced ischaemic car-
diomyopathy patient population and similar across the groups.
Importantly, this trial provides evidence for the safety and feasibil-
ity of the use of autologous cells in patients with advanced heart
failure with low peri-procedural complication rates and MACE .
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
. rates consistent with previous similar trials. Furthermore, the rise
in troponin in the i.m. group is in keeping with previously published
literature.30
Study limitations
The REGENERATE-IHD trial was designed in the same way as the
recently published REGENERATE-DCM trial.18 In order to inves-
tigate three different modes of cell therapy with the appropriate
control groups, the study population was divided into six indi-
vidual groups of 15 patients each. Small sample size as well as a
large exclusion rate among screened patients have the potential to
create a clinical selection bias despite the fact that there are no
significant differences in baseline disease markers between groups.
Despite the small sample size, the trial met its statistical primary
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Figure 5 Colony-forming unit granulocyte–monocyte (CFU
GM) count and LVEF. Significance is shown for correlations± 95%
confidence intervals.
endpoint of within-group improvement in LVEF only observed in
the i.m. BMC group. It is reasonable to suggest that this evi-
dence alone may not be enough to indicate benefit as within-group
comparisons have often been demonstrated to be unreliable and
even misleading, while between-group or two-sample methods are
favoured.25 However, clinical benefit in the i.m. BMC group is sup-
ported by the changes observed across independent surrogate
endpoints: NT-proBNP, NYHA class, as well as exploratory albeit
underpowered post-hoc between-group analysis showing benefit
of i.m. BMCs over the true control group (peripheral placebo).
This was a small Phase II trial powered around intermediate effi-
cacy measures and was not powered to detect changes in MACE
and mortality rates, as has been the case for similar trials before
it. While the trial could not be fully blinded, data analysers were
blinded to all study groups, and investigators and patients were
blinded within each arm. For pragmatic and ethical reasons, the
amount of bone marrow harvested was standardized at 50mL
rather than the dose of cells received by the patient.
Conclusion
This is an early stage Phase II exploratory randomized controlled
trial to assess whether G-CSF therapy alone or in combination
with either i.m. or i.c. delivery of BMCs improves cardiac function
in patients with advanced ischaemic heart failure with no other
treatment options. We show that the combination of G-CSF and
i.m. progenitor cell injection is safe, confers an improvement in
LVEF at 1 year of 4.99%, and is accompanied by improvement
in a panel of biochemical and symptom-related outcomes, while
other treatment groups show no significant change. The results of
REGENERATE-IHD should be considered preliminary in support
of a clinical benefit of i.m. stem cell infusion as an adjunctive
therapy in this ‘no option’ patient group. This finding should be
explored in a larger study. ..
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